Enclomiphene is the trans-isomer of clomiphene and has been studied as a way to stimulate endogenous testosterone production in men. Interest in enclomiphene is high, particularly among men who want to preserve fertility, but its regulatory status and evidence should be understood before treatment decisions are made.
Is Enclomiphene FDA Approved?
No standalone enclomiphene drug is FDA approved in the United States for treatment of male hypogonadism. This distinction matters because FDA approval requires review of safety, effectiveness and manufacturing quality for a specific product and indication.
How Enclomiphene May Affect Testosterone
By reducing estrogen feedback at the hypothalamus and pituitary, enclomiphene may increase LH and FSH signaling, which can stimulate the testes to produce testosterone and support spermatogenesis in selected men.
Potential Advantages
Theoretical advantages include increasing endogenous testosterone while preserving gonadotropin signaling, which can be relevant to fertility. However, possible advantages should not be interpreted as proof of superiority over clomiphene or other established approaches.
Potential Side Effects
Possible adverse effects may include headache, mood symptoms, changes in estradiol, visual symptoms and other effects associated with selective estrogen receptor modulation. Long-term safety data are more limited than for many established therapies.
Who Should Be Evaluated?
Men with symptoms of low testosterone should first have the diagnosis confirmed with appropriate morning testosterone testing and evaluation for reversible causes. Fertility goals, medications, sleep, obesity, pituitary disease and other contributors may change the treatment plan.
For a broader comparison, read enclomiphene vs. Clomid and visit our Clomid for Men page.
